Otros idiomas 89bio, Inc.

Acciones

ETNB

US2825591033

Tiempo real estimado Cboe BZX Otros sitios de cotización 21:43:18 30/04/2024			Varia. Cinco días.	Varia. 1 de enero.
8,605 ^USD	+0,88 %		-3,36 %	-22,83 %

17/04	89bio, Inc. nombra a Martin Babler miembro de su Consejo de Administración	CI
03/04	Un iniciado de 89bio vendió acciones por valor de 575.153 dólares, según un reciente registro de la SEC	MT

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors	17/04
89bio, Inc. Appoints Martin Babler to Its Board of Directors	17/04
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	05/04
89bio Insider Sold Shares Worth $575,153, According to a Recent SEC Filing	03/04
Sector Update: Health Care Stocks Gain Wednesday Afternoon	27/03
89bio's Liver Disease Drug Candidate Pegozafermin Gets EMA Priority Medicines Status	27/03
89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis	27/03
89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis	27/03
89bio, Inc. Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis with Fibrosis and Compensated Cirrhosis	27/03
89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis	12/03
89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis	12/03
89Bio, Inc. Announces Initiation of Its Phase 3 Enlighten Program Evaluating the Efficacy and Safety of Pegozafermin in Patients with Metabolic Dysfunction-Associated Steatohepatitis, Formerly Known as Nonalcoholic Steatohepatitis	12/03
89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(4)	11/03
89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	08/03
89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	08/03
North American Morning Briefing : Stock Futures -2-	08/03
89bio to Participate in the Leerink Partners Global Biopharma Conference	05/03
Thinking about buying stock in Aadi Bioscience, Bitdeer Technologies, Aquestive Therapeutics, 89bio, or Energem?	04/03
Top Premarket Gainers	04/03
89bio, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	29/02

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas 89bio, Inc.

Acciones

ETNB

US2825591033

Otros idiomas

Filtros